BSE Live
Nov 11, 16:01Prev. Close
1832.70
Open Price
1843.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 11, 15:58Prev. Close
1829.90
Open Price
1840.00
Bid Price (Qty.)
1817.30 (442)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
| Total Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
| Reserves and Surplus | 8,821.22 | 7,801.48 | 9,445.71 | 9,058.43 | 7,036.41 | |
| Total Reserves and Surplus | 8,821.22 | 7,801.48 | 9,445.71 | 9,058.43 | 7,036.41 | |
| Total Shareholders Funds | 8,849.44 | 7,847.93 | 9,473.92 | 9,086.65 | 7,064.63 | |
| Minority Interest | -0.37 | -0.38 | 365.34 | 351.47 | -0.35 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 512.70 | 0.00 | 3,852.14 | 2,571.74 | 3,888.82 | |
| Deferred Tax Liabilities [Net] | 58.59 | 0.28 | 42.95 | 31.50 | 28.75 | |
| Other Long Term Liabilities | 662.17 | 692.21 | 591.80 | 352.50 | 420.72 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 1,233.46 | 692.49 | 4,486.89 | 2,955.74 | 4,338.28 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,681.50 | 990.60 | 495.58 | 1,098.61 | 798.61 | |
| Trade Payables | 2,579.53 | 2,535.93 | 2,391.86 | 2,288.66 | 2,237.77 | |
| Other Current Liabilities | 1,109.92 | 1,650.94 | 1,650.54 | 810.78 | 650.31 | |
| Short Term Provisions | 596.08 | 641.12 | 507.55 | 491.38 | 514.33 | |
| Total Current Liabilities | 5,967.02 | 5,818.59 | 5,045.53 | 4,689.43 | 4,201.02 | |
| Total Capital And Liabilities | 16,049.55 | 14,358.62 | 19,371.68 | 17,083.29 | 15,603.58 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 3,319.37 | 3,118.15 | 3,904.16 | 3,690.63 | 2,957.78 | |
| Intangible Assets | 1,097.19 | 1,024.65 | 2,224.61 | 2,136.60 | 2,113.06 | |
| Capital Work-In-Progress | 541.99 | 419.32 | 1,115.18 | 921.09 | 1,217.79 | |
| Fixed Assets | 5,251.39 | 4,804.68 | 7,380.02 | 6,837.10 | 6,452.51 | |
| Non-Current Investments | 56.36 | 789.66 | 44.65 | 49.62 | 24.63 | |
| Deferred Tax Assets [Net] | 1,124.11 | 1,049.72 | 1,805.91 | 1,686.12 | 1,534.67 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 251.97 | 219.11 | 193.75 | 168.08 | 174.18 | |
| Total Non-Current Assets | 6,754.09 | 6,930.54 | 9,497.96 | 8,800.94 | 8,244.00 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 3,028.53 | 2,513.05 | 2,977.79 | 2,499.83 | 2,276.83 | |
| Trade Receivables | 3,341.95 | 1,858.41 | 4,098.61 | 3,101.14 | 2,572.06 | |
| Cash And Cash Equivalents | 1,705.23 | 1,659.46 | 1,469.70 | 1,411.52 | 1,139.16 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 1,219.76 | 1,397.16 | 1,327.63 | 1,269.87 | 1,371.53 | |
| Total Current Assets | 9,295.47 | 7,428.08 | 9,873.72 | 8,282.35 | 7,359.58 | |
| Total Assets | 16,049.55 | 14,358.62 | 19,371.68 | 17,083.29 | 15,603.58 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 936.54 | 1,193.96 | 477.58 | 559.75 | 544.81 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 15.84 | 15.84 | 15.84 | 15.84 | 15.84 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.07 | 0.05 | 0.07 | |
| Non-Current Investments Unquoted Book Value | 0.00 | 0.00 | 44.58 | 49.58 | 24.56 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015